1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
BioHarvest Sciences Inc.

BioHarvest Sciences Inc.

CNVCF
BioHarvest Sciences Inc.US flagOther OTC
6.30
USD
- -
- -
109.16MMarket Cap
BioHarvest Sciences Inc.
CNVCF
(Other OTC)

Recent

price

6.30

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
- -
0.07
0.04
0.17
0.42
0.94
1.49
Revenue per Share
-1.24
-0.58
-0.33
-0.24
-0.28
-3.14
-1.8
-0.68
-0.79
-0.86
-0.93
-1.14
Basic EPS, GAAP
-1.28
-0.34
-0.42
-0.22
-0.27
-1.03
-0.82
-0.42
-0.68
-0.8
-0.74
-0.67
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.26
-0.77
-0.86
-0.23
0.59
2.27
-9.14
-0.24
0.23
-0.45
-1.1
0.28
Book Value per Share
0.88
0.06
0.05
-0.2
0.61
-0.64
-9.14
-0.24
0.23
-0.45
-1.1
0.28
Tangible Book Value per Share
- -
- -
- -
- -
1
2
3
10
12
13
14
15
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
2
5
13
22
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
-1,026.15
-1,557.07
-403.95
-193.02
-78.65
-35
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Depreciation Expense
- -
- -
- -
- -
- -
-5
-5
-7
-10
-11
-13
-17
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
-2,435.78
-1,662.63
-467.51
-204.37
-99.15
-76.65
Profit Margin (%)
- -
- -
- -
- -
- -
1
-25
- -
3
-7
-17
-2
Working Capital
- -
- -
- -
- -
- -
- -
- -
2
2
2
1
10
LT Debt
- -
- -
- -
- -
- -
4
-27
-2
3
-6
-15
4
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
-252.89
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
8
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
9
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
17
17
Market Capitalization
96
87
85

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
8
9
8
Cash, Cash Equivalents & STI
3
5
3
Accounts Receivable, Net
1
1
1
Inventories
3
3
3
Total Current Liabilities
13
9
10
Payables & Accruals
5
8
9
ST Debt
8
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-144.16%
-259.73%
150.51%
Free Cash Flow
133.23%
47.74%
-4.77%
Net Income, GAAP
332.73%
20.56%
11.82%
Sales/Revenue/Turnover
- -
- -
130.48%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1
1
2
2
5
2023
2
3
3
5
13
2024
5
6
7
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.16
-0.18
-0.3
- -
-0.86
2023
-0.06
-0.21
-0.13
- -
-0.93
2024
-0.48
-0.04
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
HUTCHMED (China) Limited (HCM.L)
Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
Vitalibis, Inc. (VCBDQ)
Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
Curative Biosciences, Inc. (CBDX)
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF)
Business
BioHarvest Sciences Inc. (NASDAQ:BHST; CSE:BHSC; OTCQB:CNVCF) develops and commercializes proprietary Botanical Synthesis platform technology that produces plant-based molecules and therapeutic compositions at industrial scale without cultivating the underlying plant; the company operates through two primary business units offering nutraceutical products including its flagship VINIA red grape cell dietary supplement containing a full-spectrum polyphenolic matrix with amplified Piceid Resveratrol for improved blood flow, energy, and circulation supported by clinical trials, VINIA-based functional coffees generating $2.3 million in sales since December 2023 launch, VINIA SuperFood functional tea line launched November 2024, and upcoming olive and pomegranate cell compositions targeting heart, brain, optic, and sexual health indications; and contract development and manufacturing organization (CDMO) services providing custom plant cell culture development, production of patentable BIOLOGICS+ small and complex molecules with enhanced bioavailability for pharmaceutical, nutraceutical, cosmeceutical, and nutrition partners under exclusive agreements. Founded in 2007 and headquartered in Vancouver, Canada, with R&D and manufacturing operations in Rehovot and upcoming consolidation at Yavneh campus in Israel plus sales in the United States and Canada following Health Canada approval for VINIA in October 2023, BioHarvest targets health-conscious consumers via direct-to-consumer subscription models exceeding 50,000 active VINIA subscribers and B2B partners in wellness, functional foods, and biologics sectors emphasizing sustainability, ESG practices, and non-GMO outputs. Recent developments include uplisting to Nasdaq Global Market on November 12, 2024 under symbol BHST; strategic CDMO partnership with Tate & Lyle announced December 11, 2024 to co-develop next-generation plant-based sweeteners; advancement of unnamed Nasdaq-listed pharma CDMO deal to Stage 2 in May 2025 for pharmaceutical-grade compounds; October 30, 2025 announcement of saffron compound production partnership; September 2025 breakthrough in scaled plant-based exosome production for cosmetics and pharma applications containing viniferin polyphenols; $19.9 million upsized public offering closed November 2025 funding CapEx and growth; $14.7 million balance sheet strengthening via $10.9 million gross proceeds and debt reduction in September 2025; full-year 2024 revenues of $25.2 million up 99% year-over-year with Q4 at $7.3 million up 62%, gross margins expanding to 57%, and path to adjusted EBITDA breakeven in H2 2025 supported by production digitization, 22% larger bioreactors, and operational efficiencies.

Company News

APIChatGPT